Patient: Page 4
-
King’s prostate surgery puts spotlight on men’s health — and new cancer treatments on the way
The publicly announced procedure has highlighted one of the most prevalent and deadly cancers among men, and the treatments being developed to combat it.
By Michael Gibney • Jan. 25, 2024 -
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineRare diseases
As drug developers find promise in the rare diseases, deals and treatments are on the rise
By PharmaVoice staff -
Breast cancer tops list of most studied diseases
The most studied diseases last year included three types of cancer as research into COVID-19 fell sharply in the post-pandemic era.
By Kelly Bilodeau • Jan. 24, 2024 -
Controversial challenge trials offer unparalleled innovation — with ethical bumps
Demand for infectious disease treatments is projected to grow and challenge trials, when done right, could speed drug development.
By Kelly Bilodeau • Jan. 22, 2024 -
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
An enduring COVID mystery: Why some do fine and others die
The infectious disease market could be shifting toward a future not only focused on the microbe, but on the unique genetic attributes of the host.
By Alexandra Pecci • Jan. 17, 2024 -
Pharma takes a gut check of microbiome drugs
On the heels of two FDA approvals for microbiome-based therapies, interest in the space is gaining steam.
By Kelly Bilodeau • Jan. 16, 2024 -
Opinion
Pharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
Opinion // Year in Preview
PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials
As advanced therapies and patient perspectives strengthen their foothold in R&D, pharma is poised to deliver impactful treatments in record time.
By Meagan Parrish • Jan. 11, 2024 -
Regulatory twists and turns are coming for biopharma in 2024
New FDA requirements and the IRA will create complexity in the coming year. Here’s how the industry can navigate the changes.
By Kelly Bilodeau • Jan. 8, 2024 -
How J&J is tackling a ‘secondary pandemic’ in the Black community
J&J is leading a grassroots effort to improve mental health access and care.
By Alexandra Pecci • Jan. 8, 2024 -
Alzheimer’s research is hot, but successful patient recruitment will determine its future
Key strategies for bringing more patients into the clinical trial fold.
By Kelly Bilodeau • Jan. 4, 2024 -
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Deep Dive
As ALS research booms, one treatment center finds itself in the spotlight
The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists. Still, the complexities of the disease and of drug development have brought hard-felt losses.
By Jacob Bell • Dec. 22, 2023 -
What are pharma’s next blockbusters?
In a shifting market focused on targeted therapeutics, drugs that generate big profits are still a priority.
By Kelly Bilodeau • Dec. 20, 2023 -
5 noteworthy pharma AI investments in 2023
The last year showed how some of the world’s biggest pharma companies are leveraging AI tech.
By Alexandra Pecci • Dec. 19, 2023 -
Babson gets one step closer to delivering on Theranos-like blood testing
A recent FDA clearance could pave the way to pin-prick blood tests at local pharmacies and potentially one day, clinical trials.
By Kelly Bilodeau • Dec. 18, 2023 -
Study suggests PBMs are gaming pharmacy system to overcharge for drugs
Markups for generics can be as high as 7,000%, the researchers said.
By Alexandra Pecci • Dec. 15, 2023 -
Q&A
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
By Michael Gibney • Dec. 14, 2023 -
Q&A
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
By Meagan Parrish • Dec. 13, 2023 -
What’s being done to prepare for the next pandemic?
Will the world be ready when a new outbreak hits? Here’s a look at the efforts to combat emerging viral threats.
By Kelly Bilodeau • Dec. 13, 2023 -
Q&A
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023 -
Q&A // First 90 Days
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
By Alexandra Pecci • Dec. 11, 2023 -
Oncology drugmakers seek the sweet spot between efficacy and tolerability
The FDA is now pushing companies to find the optimal dose early in development to minimize harm.
By Kelly Bilodeau • Dec. 11, 2023 -
Sponsored by MedAdvisor Solutions
Increasing inflation means harder medication decisions for patients
Explore strategies for life sciences brands to simplify medication journeys for success through MedAdvisor Solutions’ THRIV™ platform, offering up to 5x more lift in adherence.
Dec. 11, 2023